This study is to define the pharmacokinetics and to evaluate the safety of BAY73-4506, 160 mg once daily administered orally as a single agent in Japanese patients with advanced solid tumors.

Inclusion Criteria:

• Male or female Japanese patients >/= 18 years
• Histologically or cytologically confirmed solid tumors
• ECOG-PS 0 - 1
• Adequate bone marrow, liver and renal function

Exclusion Criteria:

• Uncontrolled hypertension
• Patients with severe renal impairment or on dialysis
• Patients with seizure disorder requiring anticonvulsant medication
• Known or suspected allergy to the investigational agent.